Abstract
The history of asthma treatment is full of near misses. Inhaled and oral corticosteroids would not be in the therapeutic armamentarium if not for the late, great Harry Morrow-Brown's demonstration in 1958, using his medical school microscope, that these treatments worked well, but only in those with sputum eosinophilia. This early realisation of the importance of personalised medicine was rapidly forgotten in the excitement of new and powerful steroid-based treatments. Therefore, when the humanised anti-interleukin 5 (IL-5) monoclonal mepolizumab was first tested in adult asthma, it was nearly rejected as inactive until it was trialled in the right subgroup, namely patients with eosinophilic, attack-prone asthma.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
